Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 8/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987437 | 0.89 | KCNQ3 (0.54) | KCNJ11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL6984652 | 0.83 | ABCC9 (0.51) | KCNJ11GRM5S1PR3MEN1ALDH1A1 | |
| SCHEMBL4367789 | 0.83 | GRM5 (0.45) | KCNJ11GRM5KCNQ3KCNQ2KCNE1 | |
| SCHEMBL6989909 | 0.81 | KMT2A (0.41) | KCNJ11GRM5S1PR3S1PR4S1PR2 | |
| SCHEMBL6987283 | 0.81 | KMT2A (0.44) | KCNJ11GRM5S1PR3S1PR4S1PR2 | |
| SCHEMBL6989259 | 0.80 | ALDH1A1 (0.46) | KCNJ11GRM5S1PR3S1PR4S1PR2 | |
| SCHEMBL6983246 | 0.78 | KMT2A (0.44) | KCNJ11GRM5S1PR3S1PR4S1PR2 | |
| SCHEMBL6988592 | 0.78 | KCNJ11 (0.54) | KCNJ11GRM5MEN1ALDH1A1LMNA | |
| SCHEMBL6988322 | 0.77 | KCNQ3 (0.50) | KCNJ11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL6991603 | 0.76 | MEN1 (0.47) | KCNJ11GRM5MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | claimed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | claimed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | claimed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | KCNJ11 2/4885GRM5 3259/4885KCNQ3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.